Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).

被引：2
|
作者：
Davids, Matthew Steven
Roberts, Andrew Warwick
Seymour, John Francis
Gerecitano, John F.
Kahl, Brad S.
Kipps, Thomas J.
Pagel, John M.
Puvvada, Soham D.
Gressick, Lori A.
Zhu, Ming
Dunbar, Martin
Chyla, Brenda
Verdugo, Maria E.
Kim, Su Young
Wierda, William G.
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Washington Univ, St Louis, MO 63110 USA
[6] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[7] Swedish Med Ctr, Seattle, WA USA
[8] Univ Arizona, Tucson, AZ USA
[9] AbbVie Inc, N Chicago, IL USA
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7527
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7527
引用
收藏
页数：2
相关论文
共 50 条
  • [1] SAFETY, EFFICACY AND IMMUNE EFFECTS OF VENETOCLAX 400 MG DAILY IN PATIENTS (PTS) WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Anderson, M. A.
    Roberts, A. W.
    Seymour, J. F.
    Gerecitano, J. F.
    Kahl, B. S.
    Kipps, T. J.
    Pagel, J. M.
    Puvvada, S. D.
    Wierda, W. G.
    Gressick, L.
    Zhu, M.
    Dunbar, M.
    Chyla, B.
    Verdugo, M.
    Kim, S. Y.
    Davids, M. S.
    HAEMATOLOGICA, 2016, 101 : 228 - 228
  • [2] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Freise, Kevin J.
    Jones, Aksana K.
    Eckert, Doerthe
    Mensing, Sven
    Wong, Shekman L.
    Humerickhouse, Rod A.
    Awni, Walid M.
    Salem, Ahmed Hamed
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 515 - 523
  • [3] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kevin J. Freise
    Aksana K. Jones
    Doerthe Eckert
    Sven Mensing
    Shekman L. Wong
    Rod A. Humerickhouse
    Walid M. Awni
    Ahmed Hamed Salem
    Clinical Pharmacokinetics, 2017, 56 : 515 - 523
  • [4] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [5] Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients
    Ahmed, Tamer
    Hayslip, John
    Leggas, Markos
    CANCER RESEARCH, 2012, 72
  • [6] INTEGRATED SAFETY ANALYSIS OF VENETOCLAX MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Davids, M. S.
    Gerecitano, J.
    Potluri, J.
    Cerri, E.
    Kim, S. Y.
    Steinberg, M.
    Verdugo, M.
    Busman, T.
    Enschede, S. Heitner
    Mobasher, M.
    Best, A.
    Desai, M.
    Wierda, W. G.
    HAEMATOLOGICA, 2016, 101 : 59 - 59
  • [7] Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL).
    Davids, Matthew Steven
    Gerecitano, John F.
    Potluri, Jalaja
    Cerri, Elisa
    Kim, Su Young
    Steinberg, Mark
    Verdugo, Maria
    Busman, Todd A.
    Enschede, Sari H.
    Mobasher, Mehrdad
    Best, Andrea
    Desai, Monali B.
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Hallek, Michael
    Wierda, William
    Roberts, Andrew W.
    Stilgenbauer, Stephan
    Jones, Jeffrey A.
    Gerecitano, John F.
    Kim, Su Young
    Potluri, Jalaja
    Busman, Todd
    Best, Andrea
    Verdugo, Maria E.
    Cerri, Elisa
    Desai, Monali
    Hillmen, Peter
    Seymour, John F.
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4371 - 4379
  • [9] NURSING IMPLICATIONS FOR VENETOCLAX USE IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A MULTICENTER ANALYSIS
    Kennard, Kaitlin
    Howlett, Christina
    Timberg, Mary
    Staller, Emma
    Varga, Julia
    Dorsey, Colleen
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [10] The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
    Eyre, Toby A.
    Roeker, Lindsey E.
    Fox, Christopher P.
    Gohill, Satyen H.
    Walewska, Renata
    Walter, Harriet S.
    Forconi, Francesco
    Broom, Angus
    Arumainathan, Arvind
    Brander, Danielle M.
    Allan, John N.
    Schuster, Stephen J.
    Hill, Brian T.
    Lansigan, Frederick
    Cheson, Bruce D.
    Lamanna, Nicole
    Coombs, Catherine C.
    Barr, Paul M.
    Skarbnik, Alan P.
    Shadman, Mazyar
    Ujjani, Chaitra S.
    Pearson, Laurie
    Pagel, John M.
    Jacobs, Ryan
    Mato, Anthony R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 918 - 923
12345